Entremed (ENMD)

[docaaron1]

C-Peptide, thanks for the three scenarios. Just to look at it from another angle add Dr. Sidor’s quote, "We are pleased to have met the primary efficacy endpoint in the first stage of this study. We are now considering whether to continue the current study or pursue additional options such as a randomized Phase 2 study in patients with non-small cell lung cancer. We will continue to collect data over the next few months from patients participating in this trial to determine the most efficient path forward in this indication." to the end of each one.

If the results were poor, I would hope they would not want to “continue”.

If the results were great, I wonder if they would debate “or pursue additional options”.

If the results were somewhere in between, maybe borderline positive, her statement appears to fit.

Aaron